Diagnostic Consultative Center Equita OOD — Clinical Trial Site

15 Registered trials

4 Currently recruiting

Organisation

Diagnostic Consultative Center Equita OOD

Location

Varna, Bulgaria

Identifier

ORG-100044075

Address

Bulevard Tsar Osvoboditel 5, 9000, Bulgaria

Departments

504_Not applicable
Cabinet of Endocrinology and metabolic diseases
DCC Ekvita
Diagnostic Consultative Center Equita
N/A
Not Applicable
Rheumatology

Clinical trials at this site (15)

Search interface

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending

2025-523510-87-00 Obesity 5
Efficacy and Safety of KAI-9531 compared with Semaglutide in Participants Living With Obesity Who Do Not Have Diabetes Pending

2025-523511-11-00 Obesity 5
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Sjögren's Disease 5 2025-06-16
A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting

2025-521920-31-00 Graves’ Disease 4 2025-11-21
Long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus (OPUS OLE) Recruiting

2024-514354-67-00 Systemic lupus erythematosus 5 2024-11-01
SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Ended

2025-521791-63-00 Moderately to Severely Active Rheumatologic Disease 4 2025-12-18
A research study to evaluate the effects of a new oral medicine called cenerimod in adults with systemic lupus erythematosus Ended

2024-515870-28-00 Moderate to severe systemic lupus erythematosus 5 2024-10-22
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended

2023-506256-25-00 Active Psoriatic Arthritis 5 2021-10-20
A study to evaluate the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin wit… Ended

2024-511408-18-00 Type 2 Diabetes inadequately controlled with dapagliflo 5 2024-07-15
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype… Ended

2022-503022-13-00 Hypertriglyceridemia, Cardiovascular Diseases, Atherosc 5 2023-06-08
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis Ended

2024-513919-27-00 Rheumatoid arthritis 5 2017-09-14
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and… Ended

2024-512417-41-00 Osteoporosis 5